TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03477838

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FreeStyle LibrePro CGM
Description: a professional CGM device will be worn by the participant for up to 14 days
Study: NCT02519595

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine IV 1mg/kg
Description: Intervention: Ketamine IV 1mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine IV 1.5mg/kg
Description: Intervention: Ketamine IV 1.5 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine IV 2mg/kg
Description: Intervention: Ketamine IV 2 mg/kg
Study: NCT01477489

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veliparib
Description: Starting dose of veliparib will be 50 mg taken twice daily and will escalate up to a possible 200 mg twice daily.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Standard radiation treatment
Description: Limited to 60 Gy.
Study: NCT02720406

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous ketamine0.5mg/kg
Description: Intravenous ketamine 0.5mg/kg after anesthesia and before surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nebulized Ketamine 1mg/kg
Description: Nebulized Ketamine 1mg/kg given by nebulizer before anesthesia.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nebulized Ketamine 2mg/kg
Description: Nebulized Ketamine 2mg/kg given by nebulizer before anesthesia.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline placebo
Description: Saline 0.9% given by nebulizer before anesthesia and iv after anesthesia and before surgery.
Study: NCT01903629

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MCE
Description: MCE first, followed by standard gastroscopy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard gastroscopy
Study: NCT01810718

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nilotinib
Description: Maximum tolerated dosage (MTD) will be defined in Phase I. First 3 patients (pts) will receive Nilotinib 200mg daily dose. If no dose limiting toxicities after at least 1month the next 3 pts will be treated with 300mg. If are\>=2 dose limiting toxicities the Phase I will end and MTD will be defined as the next lower dosage. If they will observe 1dose limiting toxicities, they will treat other 3 pts (same dosage); if there isn't dose limiting toxicity, they will increase the dosage in the next cohort; but if they will observe another dose limiting toxicity (tot limiting toxicities 2/6 pts), the study will continue using the previous dose. MTD will be considered the maximum dosage used to treat 6 pts achieving at most 1 dose limiting toxicities, or the previous dosage if with this dosage they we will achieve 2 dose limiting toxicities. Doses will not be escalated beyond \>600 or \<200mg/die The MTD will be used for phase II
Study: NCT01270139

Intervention type: DEVICE
Group type: OTHER
Intervention: Stenting
Description: 60 - in sirolimus-eluting stenting control
Study: NCT04374331

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: video-assisted training
Description: The patients in the VAT group watch a training video in the patient rooms before RCR. The VAT prepared by the researchers consisted of information about things to pay attention to in the hospital in the early period after RCR (nursing care on post-operative day 1, early mobilization, pain control, shoulder protection, and wearing/removing the shoulder sling), maintaining ADL at home (bathing, nutrition, eating, sleeping position, driving, doing household chores, sexual life, worship, and safety measures to be taken at home) and gradual exercise programs (for the first 90 days after discharge).
Study: NCT00265382

Intervention type: DRUG
Group type: OTHER
Intervention: Ziprasidone oral capsules
Description: Study medications will include oral ziprasidone capsules of 20 mg, 40 mg, 60 mg, and 80 mg strength. Subjects will be dosed daily for 26 weeks using a flexible dose design with a minimal dose range of 20mg bid to a maximum dose range of 80 mg bid.
Study: NCT02460185

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Study group: Maternal Physical Exercise
Description: Exercise: 30 minutes of walking, 3 times a week at 4 Km/h.
Study: NCT02395445

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: orotracheal intubation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: orotracheal intubation
Study: NCT03372304

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.2%
Description: Perineural infusion of Ropivacaine 0.2% using a peripheral nerve block catheter and a portable infusion pump.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 0.2%
Description: Perineural infusion of Ropivacaine 0.2% using a peripheral nerve block catheter and a portable infusion pump.
Study: NCT03848936

Intervention type: OTHER
Intervention: Survey
Description: Survey includes age, gender, cerebral palsy type, education, mental status, working status, living conditions, comorbidities, pain, spasticity, contractures, deformities, mobility status and gross motor function classification system level
Study: NCT02397057

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Injectafer

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04403815

Intervention type: PROCEDURE
Intervention: vascular access for coronary procedures
Description: comparison of x-rays exposition of interventional cardiologist according to vascular access used
Study: NCT03372304

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 0.2%
Description: Perineural infusion of Ropivacaine 0.2% using a peripheral nerve block catheter and a portable infusion pump.
Study: NCT03639493

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exforge® tab 10/160mg, Crestor® tab 20mg
Description: Co-administration of Amlodipine 10mg/ Valsartan 160mg(combination drug) and Rosuvastatin 20mg
Study: NCT02518633

Intervention type: DEVICE
Intervention: Continuous positive airway pressure devices
Description: overnight use of CPAP device
Study: NCT03120715

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: estrogen
Description: The oral estrogen replacement is 4mg per day (2 mg twice daily), 4 days; 6 mg per day, 4 days. Then, the patient's endometrial thickness is evaluated through vaginal ultrasound and if the endometrial thickness is \<7 mm, increasing estrogen by 2 mg is given to patients until the endometrial thickness is \>9 mm.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: estrogen
Description: The oral estrogen replacement is 4mg per day (2 mg twice daily), 4 days; 6 mg per day, 4 days. Then, the patient's endometrial thickness is evaluated through vaginal ultrasound and if the endometrial thickness is \<7 mm, increasing estrogen by 2 mg is given to patients until the endometrial thickness is \>9 mm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Molecular Weight Heparin
Description: If the endometrial thickness is greater than 9 mm, hCG 10000 IU will be administered via intramuscular injection.And low molecular weight heparin (LMWH) will be injected subcutaneously 4100 IU (WHO) every other day before FET.Then on the next day(D0), progesterone in oil 60 mg will be administered via intramuscular injection. Transfer of thawed embryos will be performed 3 days later(D3).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hCG
Description: If the endometrial thickness is greater than 9 mm, Human Chorionic Gonadotropin（hCG） 10000 IU will be administered via intramuscular injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: hCG
Description: If the endometrial thickness is greater than 9 mm, Human Chorionic Gonadotropin（hCG） 10000 IU will be administered via intramuscular injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: progesterone
Description: on the next day(D0), progesterone in oil 60 mg will be administered via intramuscular injection. Transfer of thawed embryos will be performed 3 days later(D3).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: progesterone
Description: on the next day(D0), progesterone in oil 60 mg will be administered via intramuscular injection. Transfer of thawed embryos will be performed 3 days later(D3).
Study: NCT02741427

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Conventional toothpaste
Description: The participants should brush their teeth with conventional toothpaste for 90 seconds, twice per day, during two weeks.They should place a pea-size amount of toothpaste on their toothbrushes, use dental floss, but not mouth rinse.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whitening toothpaste
Description: The subjects should brush teeth with whitening toothpaste containing blue pigment for 90 seconds, twice per day, during two weeks.They should place a pea-size amount of toothpaste on toothbrushes, use dental floss, but not mouth rinse.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 10% carbamide peroxide
Description: The subjects should dispense the bleaching gel at night into the trays (maxillary and mandibular) and to insert them to cover at least the anterior teeth for a period of 4 h per day, over a 2-week period. Both arches should be bleached at the same time. During the period of bleaching, volunteers should receive the same toothpaste used by G1, in other words, without whitening agents, to standardize their oral hygiene regimen
Study: NCT03639493

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exforge® tab 10/160mg, Crestor® tab 20mg
Description: Co-administration of Amlodipine 10mg/ Valsartan 160mg(combination drug) and Rosuvastatin 20mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CJ-30060 10/160/20mg
Description: Fixed-dose combination drug containing Amlodipine 10mg and Valsartan 160mg and Rosuvastatin 20mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CJ-30060 10/160/20mg
Description: Fixed-dose combination drug containing Amlodipine 10mg and Valsartan 160mg and Rosuvastatin 20mg
Study: NCT00523081

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Description: Half the teens in the study will also meet with a research counselor for five to nine individual, weekly sessions that last about 50 minutes each. Whether a teen attends the weekly counseling sessions is decided by chance, like flipping a coin. If teens are assigned to these sessions, they will learn ways to deal with stress and feel better. If teens take part in the counseling sessions, the study counselor will also talk to the teen's doctor from time to time to help plan for the best possible care.
Study: NCT03230539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ulipristal Acetate IUS delivering Cu and 5μg
Description: This is a proof-of-concept study utilizing a randomized dose-finding, parallel design to assess the effects of an IUS delivering Cu and 5, 20, or 40 μg of UPA over 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ulipristal Acetate IUS delivering Cu and 20μg
Description: This is a proof-of-concept study utilizing a randomized dose-finding, parallel design to assess the effects of an IUS delivering Cu and 5, 20, or 40 μg of UPA over 12 weeks.
Study: NCT00523081

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active control
Description: Teens in the active control arm will keep seeing their doctor as usual. Teens and a parent are interviewed briefly over the phone to see if they are appropriate for the study. If they qualify for the study, there is an hour-long interview with teen over the telephone and a 30 minute interview with the parent. They will be interviewed six more times in the next two years.
Study: NCT02085109

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fat milkshake

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fat milkshake
Study: NCT03230539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ulipristal Acetate IUS delivering Cu and 40μg
Description: This is a proof-of-concept study utilizing a randomized dose-finding, parallel design to assess the effects of an IUS delivering Cu and 5, 20, or 40 μg of UPA over 12 weeks.
Study: NCT02735382

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tobacco quitline EHR referral
Description: Using an EHR-based referral to the tobacco quitline from primary care outpatient clinics.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tobacco quitline EHR referral
Description: Using an EHR-based referral to the tobacco quitline from primary care outpatient clinics.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Tobacco quitline Fax referral
Description: Using an Fax--based referral to the tobacco quitline from primary care outpatient clinics.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Tobacco quitline Fax referral
Description: Using an Fax--based referral to the tobacco quitline from primary care outpatient clinics.
Study: NCT02369874

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI4736
Description: MEDI4736 Monotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI4736 + Tremelimumab
Description: MEDI4736 + Tremelimumab combination therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard of Care
Study: NCT00758628

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bromefenac
Description: Bromfenac BID 3 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Blink
Description: Blink BID for 3 months
Study: NCT01503866

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bardoxolone methyl
Description: oral, single dose
Study: NCT04081727

Intervention type: DEVICE
Group type: OTHER
Intervention: Zip-stitch(TM)
Description: The assigned intervention is used to close the cuff following colpotomy.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zip-stitch(TM)
Description: The assigned intervention is used to close the cuff following colpotomy.
Study: NCT02085109

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Fat milkshake
Study: NCT01347138

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: case management
Description: confirmation of hospital visit date, checking the adverse effect and treatment compliance
Study: NCT02085109

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Theobromine
Study: NCT01802125

Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT03303833

Intervention type: OTHER
Intervention: No intervention, observational study.
Study: NCT03288922

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Limited BF OL-HDF with SHF
Description: The new modality Limited BF OL-HDF with SHF were performed using Fresenius 5008 hemodiafiltration machine. The prescribed blood flow rate was 300 ml/min and the total dialysis fluid flow rate was 800 ml/min which included pre-filter substitution rate of 150 ml/min. The super high-flux dialyzer was PES-17Dα from Nipro Corporation, Japan which contains 1.7 m2 hollow fiber polyethersulfone membrane (ultrafiltration coefficient 80 ml/h/mmHg; urea clearance 267 ml/min, Qb 300 ml/min and Qd 500ml/min). The patients were received this treatment thrice-a-week for 2 week before entering the wash-out period and crossover to another arm.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: High-efficiency OL-HDF
Description: The controlled modality High-efficiency OL-HDF were performed using Fresenius 5008 hemodiafiltration machine. The prescribed blood flow rate was 400 ml/min and the total dialysis fluid flow rate was 800 ml/min which included post-filter substitution rate of 100 ml/min. The standard high-flux dialyzer that was used was HF80s from Fresenius Medical Care, Germany contains 1.8 m2 hollow fiber polysulfone membrane (ultrafiltration coefficient 55 ml/h/mmHg; urea clearance 248 ml/min, Qb 300ml/min and Qd 500 ml/min). The patients were received this treatment thrice-a-week for 2 week before entering the wash-out period and crossover to another arm.
Study: NCT03512379

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TIANJI Robot
Description: A robotic system for spinal surgery

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fluoroscopy
Description: For fluoroscopy-based free hand surgery

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Navigation
Description: For navigation-assisted spinal surgery
Study: NCT00349778

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide as a white powder in 100 mg, 200 mg and 500 mg vials, to be dissolved in \~250 mL of saline or D5W and infused IV over 2 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 100 mg etoposide as 5 mL solution in clear ampules for injection.
Study: NCT02946736

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FSSB/Sleep Leadership Training
Description: Supervisors will receive a training addressing family-supportive supervisor behaviors and sleep leadership.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Actigraphy Feedback
Description: Supervisors and employees will receive personalized feedback on their sleep and activity measurements.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Actigraphy Feedback
Description: Supervisors and employees will receive personalized feedback on their sleep and activity measurements.
Study: NCT03072927

Intervention type: DEVICE
Intervention: MILD
Description: MILD is performed under fluoroscopic image guidance through an ipsilateral interlaminar dorsal approach to the spine. Following epidurography, partial decompression is performed through the removal of tissue and bone at the symptomatic level confirmed with correlated MRI and clinical findings.

Intervention type: DEVICE
Intervention: Interspinous Process Decompression
Description: Interspinous Process Decompression
Study: NCT04301557

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 Antibody
Description: PD-1 antibody 240mg,I.V,D1,repeat every 3 weeks, Four cycles in the neoadjuvant treatment, and four cycles in the adjuvant treatment,

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxiliplatin 130mg/m\^2 (100mg/m\^2 during radiotherapy),I.V,D1,repeat every 3 weeks, Four cycles in the neoadjuvant treatment in Capeox regimen, and two cycles in the adjuvant treatment in Capeox regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine 1000mg/m\^2,Bid,P.O,D1-D14,repeat every 3 weeks, Four cycles in the neoadjuvant treatment in Capeox regimen, and two cycles in the adjuvant treatment in Capeox regimen, and two cycles in adjuvant treatment in Capecitabine regimen

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External beam radiotherapy
Description: Neoadjuvant radiotherapy, 50Gy/25Fractions to the GTV, 45Gy/25Fractions to the CTV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total mesorectal excision
Description: Total mesorectal excision
Study: NCT00511602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Technosphere Insulin
Description: Technosphere Insulin Inhalation Powder

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Technosphere Placebo
Description: Technosphere Inhalation Powder
Study: NCT02207634

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: Administered subcutaneously using a spring-based prefilled 1.0 mL autoinjector/pen.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered subcutaneously using a spring-based prefilled 1.0 mL autoinjector/pen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Background Statin Therapy
Description: Participants were required to be on a stable, high- to moderate-intensity statin background therapy consisting of an effective statin dose, ie, at least atorvastatin 20 mg daily or equivalent, and where locally approved, highly effective statin therapy (defined as at least atorvastatin 40 mg daily or equivalent) was recommended.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Background Statin Therapy
Description: Participants were required to be on a stable, high- to moderate-intensity statin background therapy consisting of an effective statin dose, ie, at least atorvastatin 20 mg daily or equivalent, and where locally approved, highly effective statin therapy (defined as at least atorvastatin 40 mg daily or equivalent) was recommended.
Study: NCT05850117

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: esomeprazole, tripotassium dicitrate bismuthate, tetracycline and levofloxacin
Description: Tetracycline combined with levofloxacin quadruple therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: esomeprazole , tripotassium dicitrate bismuthate, tetracycline 500mg and metronidazole
Description: standard tincture quadruple therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: esomeprazole, tripotassium dicitrate bismuthate , amoxicillin and levofloxacin
Description: amoxicillin combined with levofloxacin quadruple therapy
Study: NCT02757755

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AB-SA01 (10^8 PFU per phage)
Description: Gauze pads will be saturated with AB-SA01 and then applied to each subject's volar forearm and covered with occlusive dressing once daily for 3 consecutive days. Placement of the gauze to each subject's right or left volar forearm will be randomized and double-blinded.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AB-SA01 (10^9 PFU per phage)
Description: Gauze pads will be saturated with AB-SA01 and then applied to each subject's volar forearm and covered with occlusive dressing once daily for 3 consecutive days. Placement of the gauze to each subject's right or left volar forearm will be randomized and double-blinded.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo (for Cohort 10^8)
Description: Gauze pads will be saturated with Placebo and then applied to each subject's volar forearm and covered with occlusive dressing once daily for 3 consecutive days. Placement of the gauze to each subject's right or left volar forearm will be randomized and double-blinded.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo (for Cohort 10^9)
Description: Gauze pads will be saturated with Placebo and then applied to each subject's volar forearm and covered with occlusive dressing once daily for 3 consecutive days. Placement of the gauze to each subject's right or left volar forearm will be randomized and double-blinded.
Study: NCT02920801

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: saxagliptin
Description: 5mg per day for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: 1500mg per day for 12 weeks
Study: NCT02347059

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-dopa
Description: Antiparkinsonian medication

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dopamine Agonists (pramipexole, ropirinole)
Description: Antiparkinsonian medication